GERON CORP GERN

Latest FY: 2025 Healthcare Biotechnology
Market Price $1.50
Market Cap $962.28M
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑133.4% YoY
$328.01M
3-Yr CAGR: 719.5%
Net Income ↑52.2% YoY
-$83.50M
Net Margin: -25.5%
Free Cash Flow ↑49.3% YoY
-$111.09M
FCF Yield: -11.54%
EPS (Diluted) ↑51.9% YoY
$-0.13
Basic: $-0.13
Return on Equity Efficiency
-37.0%
ROA: -14.6%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (GERN)

All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
  • FY 2017: Revenue YoY (-82.7%) is identical to Gross Profit YoY (-82.7%). Verify the underlying Revenue and Gross Profit values for FY 2017 and FY 2016.
  • FY 2018: Revenue YoY (+0.1%) is identical to Gross Profit YoY (+0.1%). Verify the underlying Revenue and Gross Profit values for FY 2018 and FY 2017.
  • FY 2019: Revenue YoY (-56.8%) is identical to Gross Profit YoY (-56.8%). Verify the underlying Revenue and Gross Profit values for FY 2019 and FY 2018.
  • FY 2020: Revenue YoY (-45.0%) is identical to Gross Profit YoY (-45.0%). Verify the underlying Revenue and Gross Profit values for FY 2020 and FY 2019.
  • FY 2021: Revenue YoY (+450.6%) is identical to Gross Profit YoY (+450.6%). Verify the underlying Revenue and Gross Profit values for FY 2021 and FY 2020.
  • FY 2022: Revenue YoY (-57.2%) is identical to Gross Profit YoY (-57.2%). Verify the underlying Revenue and Gross Profit values for FY 2022 and FY 2021.
  • FY 2023: Revenue YoY (-60.2%) is identical to Gross Profit YoY (-60.2%). Verify the underlying Revenue and Gross Profit values for FY 2023 and FY 2022.
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $6.2M $6.2M $-29.5M $-0.19 0.00% $-18.4M $-18.4M
FY 2017 $1.1M -82.7% $1.1M $-27.9M +5.5% $-0.18 +5.3% 0.00% $-20.6M $-20.6M -11.9%
FY 2018 $1.1M +0.1% $1.1M $-27.0M +3.2% 0.00% $-21.0M $-21.0M -2.0%
FY 2019 $0.5M -56.8% $0.5M $-68.5M -153.7% 0.00% $-43.8M $-44.2M -110.4%
FY 2020 $0.3M -45.0% $0.3M $-75.6M -10.3% $-0.28 0.00% $-66.7M $-67.1M -51.6%
FY 2021 $1.4M +450.6% $1.4M $-116.1M -53.6% $-0.35 -25.0% 0.00% $-95.6M $-95.8M -42.8%
FY 2022 $0.6M -57.2% $0.6M $-141.9M -22.2% $-0.37 -5.7% 0.00% $-127.4M $-127.8M -33.5%
FY 2023 $0.2M -60.2% $0.2M $-184.1M -29.8% $-0.32 +13.5% 0.00% $-167.7M $-168.6M -31.9%
FY 2024 $140.6M +59,210.5% $122.1M $-174.6M +5.2% $-0.27 +15.6% 0.00% $-218.6M $-219.3M -30.1%
FY 2025 $328.0M +133.4% $295.4M $-83.5M +52.2% $-0.13 +51.9% 0.00% $-111.0M $-111.1M +49.3%
$

Valuation

Market Price $1.50
Market Cap $962.28M
Enterprise Value $1.00B
P/E Ratio N/A
P/B Ratio 4.27
FCF Yield -11.54%
Dividend Yield N/A
Shares Outstanding 641,521,000
%

Profitability & Margins

Gross Margin 90.04%
Operating Margin -20.91%
Net Margin -25.46%
Return on Equity (ROE) -36.97%
Return on Assets (ROA) -14.64%
Asset Turnover 0.57x
Revenue 3-Yr CAGR 719.50%
🛡️

Financial Health & Liquidity

Current Ratio 4.66
Cash Ratio 0.70
Debt / Equity 0.529
Debt / Assets 0.210
Cash & Equivalents $77.56M
Total Debt $119.55M
Book Value / Share $0.35
💧

Cash Flow Efficiency

Operating Cash Flow -$111.04M
Capital Expenditures (CapEx) $49.00K
Free Cash Flow -$111.09M
OCF / Revenue -33.85%
FCF / Revenue -33.87%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $-0.13
EPS (Basic) $-0.13
Dividends / Share N/A
Book Value / Share $0.35
EPS YoY Growth 51.85%
🏛️

Balance Sheet (FY 2025)

Total Assets $570.54M
Total Liabilities $344.67M
Stockholders' Equity $225.87M
Current Assets $520.27M
Current Liabilities $111.54M